Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 6/20 | 0.86 |
| ▸ | ENPP1 | P22413 | 4/20 | 0.86 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.86 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.85 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.85 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.85 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.85 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.85 |
| ▸ | BLM | P54132 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.79 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2527383 | 1.00 | P2RY1 (0.86) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| SCHEMBL8862410 | 1.00 | P2RY1 (0.86) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| SCHEMBL16700299 | 0.96 | P2RY1 (0.80) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| SCHEMBL195864 | 0.93 | P2RY1 (1.00) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| SCHEMBL18089710 | 0.93 | P2RY1 (1.00) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| SCHEMBL195865 | 0.93 | P2RY1 (1.00) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| SCHEMBL12216627 | 0.93 | P2RY1 (0.95) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| SCHEMBL2463601 | 0.93 | P2RY1 (0.81) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| SCHEMBL29381860 | 0.92 | P2RY1 (1.00) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| SCHEMBL10120953 | 0.92 | P2RY1 (1.00) | P2RY1ENPP1P2RY12P2RY11P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299097-B2 | Methods for treating inflammatory disorders | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100081684-A1 | METHODS FOR TREATING INFLAMMATORY DISORDERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-7405051-B2 | Method of screening antiplatelet agents | ASTELLAS PHARMA INC. (JP) | 2008-07-29 | — | — | US | disclosed |
| EP-1331228-B1 | METHOD OF SCREENING ANTIPLATELET | ASTELLAS PHARMA INC (JP) | 2007-03-21 | — | — | EP | disclosed |
| EP-1331228-A1 | METHOD OF SCREENING ANTIPLATELET | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-07-30 | — | — | EP | disclosed |
| US-20030124626-A1 | Method of screening antiplatelet | ASTELLAS PHARMA INC. (JP) | 2003-07-03 | — | — | US | disclosed |
| US-6562514-B1 | Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries | PINNACLE VRB LIMITED (AU) | 2003-05-13 | — | — | US | disclosed |
| US-6468688-B2 | CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE | PINNACLE VRB LIMITED (AU) | 2002-10-22 | — | — | US | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| EP-0683789-A1 | N-ALKYL-2-SUBSTITUTED ATP ANALOGUES | Astra Pharmaceuticals Limited (GB) | 1995-11-29 | — | — | EP | disclosed |
| EP-0508687-B1 | ATP analogues | FISONS PLC (GB) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
| WO-1994018216-A1 | N-ALKYL-2-SUBSTITUTED ATP ANALOGUES | ASTRA PHARMACEUTICALS LIMITED (GB) | 1994-08-18 | — | — | WO | disclosed |
| EP-0579643-A1 | ATP ANALOGUES | FISONS plc (GB) | 1994-01-26 | — | — | EP | disclosed |
| WO-1992017488-A1 | ATP ANALOGUES | FISONS PLC (GB) | 1992-10-15 | — | — | WO | disclosed |
| EP-0508687-A1 | ATP analogues | Astra Pharmaceuticals Limited (GB) | 1992-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081684-A1 | METHODS FOR TREATING INFLAMMATORY DISORDERS | LTB4R2, LTB4R, LTC4S | P2RY1 108/4885ENPP1 542/4885P2RY12 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.